[Pomalidomide/cyclophosphamide/dexamethasone combination therapy for relapsed/refractory multiple myeloma accompanied by extramedullary lesions].
Cyclophosphamide
Extramedullary myeloma
Pomalidomide
Journal
[Rinsho ketsueki] The Japanese journal of clinical hematology
ISSN: 0485-1439
Titre abrégé: Rinsho Ketsueki
Pays: Japan
ID NLM: 2984782R
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
6
2
2020
pubmed:
6
2
2020
medline:
19
2
2020
Statut:
ppublish
Résumé
We retrospectively evaluated the efficacy of pomalidomide/cyclophosphamide/dexamethasone (PCd) treatment in seven patients with extramedullary disease (EMD). Three of the seven patients achieved VGPR (very good partial response) with PCd therapy. We handled a patient complicated with secondary plasma cell leukemia, which was completely cured with PCd regimen and succeeded to autologous stem cell transplantation. In addition, there were no severe infections during the treatment period. This is the first report demonstrating the efficiency and tolerability of PCd treatment for EMD.
Identifiants
pubmed: 32023597
doi: 10.11406/rinketsu.61.20
doi:
Substances chimiques
Thalidomide
4Z8R6ORS6L
Dexamethasone
7S5I7G3JQL
Cyclophosphamide
8N3DW7272P
pomalidomide
D2UX06XLB5
Types de publication
Journal Article
Langues
jpn
Sous-ensembles de citation
IM